Table 2.
Treatment effect for the primary and secondary outcome measures (intention-to-treat).
| Outcome measure |
Control group (n = 102) |
Intervention group (n = 93) |
Treatment effect (6 months) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Mean ± SD (linear mixed models) |
Unadjusted |
Adjusted* |
||||||||
| Baseline | 3 months | 6 months | Baseline | 3 months | 6 months | MD (95% CI) | P value | MD (95% CI) | P value | |
| Physical activitya | 38.9 ± 22.6 | 39.8 ± 25.9 | 39.9 ± 26.1 | 37.5 ± 21.1 | 43.3 ± 20.7 | 44.2 ± 24.4 | 2.92 (–6.2; 12.1) | 0.52 | 2.49 (–2.1; 7.1) | 0.28 |
| Physical activityb | 50.7 ± 33.4 | 52.3 ± 35.4 | 65.4 ± 48.8 | 49.4 ± 29.6 | 56.8 ± 29.7 | 69.4 ± 46.8 | 3.57 (–8.4; 15.5) | 0.55 | 2.41 (–4.3; 9.1) | 0.48 |
| Daily sedentary timec | 82.6 ± 5.7 | 82.5 ± 5.8 | 82.9 ± 5.9 | 83.3 ± 5.5 | 83.0 ± 5.9 | 83.3 ± 5.3 | 0.54 (–1.5; 2.6) | 0.60 | 0.31(–0.6; 1.9) | 0.50 |
| Exercise Self-efficacy Scale | 51.8 ± 17.7 | 57.7 ± 16.8 | 59.0 ± 16.7 | 49.4 ± 17.1 | 57.0 ± 17.3 | 58.8 ± 16.0 | –0.82 (–5.8; 4.2) | 0.75 | –0.79 (–4.6; 3.0) | 0.68 |
| PAM-13 | 59.2 ± 12.2 | 60.1 ± 14.0 | 61.6 ± 11.9 | 57.2 ± 12.2 | 59.9 ± 12.7 | 59.7 ± 14.0 | –1.59 (–5.4; 2.2) | 0.41 | 0.03 (–2.9; 3.0) | 0.99 |
|
Mean ± SD (ANCOVA) |
|
|
Standardised coefficients (95% CI) |
P value |
||||||
| EQ-5D-3L | 0.8 ± 0.2 | NA | 0.8 ± 0.2 | 0.8 ± 0.2 | NA | 0.8 ± 0.2 | 0.02 (0.0; 0.05) | 0.17 | ||
| EQ VAS score | 73.6 ± 14.1 | NA | 75.2 ± 14.6 | 67.3 ± 14.7 | NA | 70.0 ± 12.4 | 0.16 (–3.2; 3.5) | 0.92 | ||
CI: confidence interval; MD: mean difference; NA: not applicable; PAM-13: patient activation measure short form; VAS: visual analogue scale.
aDaily minutes of moderate to vigorous physical activity.
bObjective daily minutes of moderate to vigorous physical activity measured with the accelerometer added with self-reported cycling, swimming, strength training.
cPercentage of the wear time spent in the sedentary category (<1.8 METS).
*Adjusted for baseline measurement.